Auriga Downgrades Myriad Genetics To Hold, Lowers PT To $25

Loading...
Loading...
Auriga has downgraded Myriad Genetics
MYGN
from Buy to Hold and has lowered the price target from $27 to $25.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: DowngradesPrice TargetAnalyst RatingsAuriga USABiotechnologyHealth CareMyriad Genetics
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...